nodes	percent_of_prediction	percent_of_DWPC	metapath
Tazarotene—Skin irritation—Valrubicin—urinary bladder cancer	0.0356	0.0867	CcSEcCtD
Tazarotene—RARB—prostate gland—urinary bladder cancer	0.0237	0.129	CbGeAlD
Tazarotene—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.0205	0.0507	CbGpPWpGaD
Tazarotene—RARG—prostate gland—urinary bladder cancer	0.0194	0.105	CbGeAlD
Tazarotene—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.0184	0.0454	CbGpPWpGaD
Tazarotene—RARA—prostate gland—urinary bladder cancer	0.0182	0.0989	CbGeAlD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.0176	0.0436	CbGpPWpGaD
Tazarotene—Burning sensation—Mitomycin—urinary bladder cancer	0.0153	0.0372	CcSEcCtD
Tazarotene—Stinging—Mitomycin—urinary bladder cancer	0.0131	0.0319	CcSEcCtD
Tazarotene—RARG—urethra—urinary bladder cancer	0.013	0.0704	CbGeAlD
Tazarotene—RARB—female reproductive system—urinary bladder cancer	0.0129	0.0704	CbGeAlD
Tazarotene—Leukoderma—Thiotepa—urinary bladder cancer	0.0126	0.0305	CcSEcCtD
Tazarotene—RARA—renal system—urinary bladder cancer	0.0124	0.0674	CbGeAlD
Tazarotene—RARB—vagina—urinary bladder cancer	0.0117	0.0636	CbGeAlD
Tazarotene—RXRB—vagina—urinary bladder cancer	0.0108	0.0585	CbGeAlD
Tazarotene—RARG—female reproductive system—urinary bladder cancer	0.0106	0.0574	CbGeAlD
Tazarotene—Skin irritation—Fluorouracil—urinary bladder cancer	0.0102	0.0248	CcSEcCtD
Tazarotene—Application site pain—Fluorouracil—urinary bladder cancer	0.01	0.0244	CcSEcCtD
Tazarotene—RARA—female reproductive system—urinary bladder cancer	0.00993	0.054	CbGeAlD
Tazarotene—RARG—vagina—urinary bladder cancer	0.00955	0.0519	CbGeAlD
Tazarotene—Skin hyperpigmentation—Thiotepa—urinary bladder cancer	0.00898	0.0218	CcSEcCtD
Tazarotene—RARG—Nuclear Receptors—ESR2—urinary bladder cancer	0.00798	0.0197	CbGpPWpGaD
Tazarotene—Oedema peripheral—Valrubicin—urinary bladder cancer	0.00763	0.0185	CcSEcCtD
Tazarotene—RARB—lymph node—urinary bladder cancer	0.00757	0.0412	CbGeAlD
Tazarotene—Skin hyperpigmentation—Fluorouracil—urinary bladder cancer	0.00743	0.0181	CcSEcCtD
Tazarotene—RARB—Nuclear Receptors—ESR2—urinary bladder cancer	0.00716	0.0177	CbGpPWpGaD
Tazarotene—CYP2C8—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00688	0.017	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors—ESR2—urinary bladder cancer	0.00686	0.017	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptors—ESR2—urinary bladder cancer	0.00686	0.017	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptor transcription pathway—ESR2—urinary bladder cancer	0.00631	0.0156	CbGpPWpGaD
Tazarotene—RARG—lymph node—urinary bladder cancer	0.00618	0.0336	CbGeAlD
Tazarotene—Blister—Fluorouracil—urinary bladder cancer	0.00613	0.0149	CcSEcCtD
Tazarotene—Sensitisation—Epirubicin—urinary bladder cancer	0.00602	0.0146	CcSEcCtD
Tazarotene—RARG—RXR and RAR heterodimerization with other nuclear receptor—PPARG—urinary bladder cancer	0.00598	0.0148	CbGpPWpGaD
Tazarotene—Skin discolouration—Thiotepa—urinary bladder cancer	0.00591	0.0144	CcSEcCtD
Tazarotene—RARA—lymph node—urinary bladder cancer	0.00581	0.0316	CbGeAlD
Tazarotene—Discomfort—Valrubicin—urinary bladder cancer	0.00567	0.0138	CcSEcCtD
Tazarotene—RARB—Nuclear Receptor transcription pathway—ESR2—urinary bladder cancer	0.00566	0.014	CbGpPWpGaD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00558	0.0138	CbGpPWpGaD
Tazarotene—Sensitisation—Doxorubicin—urinary bladder cancer	0.00557	0.0135	CcSEcCtD
Tazarotene—Stinging—Fluorouracil—urinary bladder cancer	0.00545	0.0133	CcSEcCtD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—ESR2—urinary bladder cancer	0.00542	0.0134	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptor transcription pathway—ESR2—urinary bladder cancer	0.00542	0.0134	CbGpPWpGaD
Tazarotene—Leukoderma—Methotrexate—urinary bladder cancer	0.00541	0.0131	CcSEcCtD
Tazarotene—RARB—RXR and RAR heterodimerization with other nuclear receptor—PPARG—urinary bladder cancer	0.00537	0.0133	CbGpPWpGaD
Tazarotene—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.00534	0.0132	CbGpPWpGaD
Tazarotene—Dermatitis contact—Thiotepa—urinary bladder cancer	0.00528	0.0128	CcSEcCtD
Tazarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—PPARG—urinary bladder cancer	0.00514	0.0127	CbGpPWpGaD
Tazarotene—RARA—RXR and RAR heterodimerization with other nuclear receptor—PPARG—urinary bladder cancer	0.00514	0.0127	CbGpPWpGaD
Tazarotene—RARG—Retinoic acid receptors-mediated signaling—CREBBP—urinary bladder cancer	0.00513	0.0127	CbGpPWpGaD
Tazarotene—Skin exfoliation—Thiotepa—urinary bladder cancer	0.0051	0.0124	CcSEcCtD
Tazarotene—Leukoderma—Epirubicin—urinary bladder cancer	0.00506	0.0123	CcSEcCtD
Tazarotene—CYP2C8—renal system—urinary bladder cancer	0.00491	0.0267	CbGeAlD
Tazarotene—RARG—Nuclear Receptors—ESR1—urinary bladder cancer	0.00484	0.012	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.00483	0.0119	CbGpPWpGaD
Tazarotene—Leukoderma—Doxorubicin—urinary bladder cancer	0.00468	0.0114	CcSEcCtD
Tazarotene—Erythema—Mitomycin—urinary bladder cancer	0.00464	0.0113	CcSEcCtD
Tazarotene—RARB—Retinoic acid receptors-mediated signaling—CREBBP—urinary bladder cancer	0.0046	0.0114	CbGpPWpGaD
Tazarotene—Inflammation—Fluorouracil—urinary bladder cancer	0.00455	0.0111	CcSEcCtD
Tazarotene—RARG—Nuclear Receptors—PPARG—urinary bladder cancer	0.00442	0.0109	CbGpPWpGaD
Tazarotene—RARA—Retinoic acid receptors-mediated signaling—CREBBP—urinary bladder cancer	0.00441	0.0109	CbGpPWpGaD
Tazarotene—RXRB—Retinoic acid receptors-mediated signaling—CREBBP—urinary bladder cancer	0.00441	0.0109	CbGpPWpGaD
Tazarotene—Dermatitis contact—Fluorouracil—urinary bladder cancer	0.00437	0.0106	CcSEcCtD
Tazarotene—Pain—Carboplatin—urinary bladder cancer	0.00436	0.0106	CcSEcCtD
Tazarotene—RARB—Nuclear Receptors—ESR1—urinary bladder cancer	0.00434	0.0107	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.00433	0.0107	CbGpPWpGaD
Tazarotene—Skin exfoliation—Gemcitabine—urinary bladder cancer	0.00429	0.0104	CcSEcCtD
Tazarotene—Skin discolouration—Etoposide—urinary bladder cancer	0.00425	0.0103	CcSEcCtD
Tazarotene—RXRB—Nuclear Receptors—ESR1—urinary bladder cancer	0.00416	0.0103	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors—ESR1—urinary bladder cancer	0.00416	0.0103	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.00415	0.0103	CbGpPWpGaD
Tazarotene—Skin exfoliation—Cisplatin—urinary bladder cancer	0.004	0.00972	CcSEcCtD
Tazarotene—RARB—Nuclear Receptors—PPARG—urinary bladder cancer	0.00396	0.00979	CbGpPWpGaD
Tazarotene—Inflammation—Etoposide—urinary bladder cancer	0.00396	0.00962	CcSEcCtD
Tazarotene—CYP2C8—female reproductive system—urinary bladder cancer	0.00393	0.0214	CbGeAlD
Tazarotene—Discomfort—Mitomycin—urinary bladder cancer	0.00391	0.0095	CcSEcCtD
Tazarotene—Pruritus—Valrubicin—urinary bladder cancer	0.00389	0.00946	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Methotrexate—urinary bladder cancer	0.00386	0.00939	CcSEcCtD
Tazarotene—RARG—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.00383	0.00945	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptors—PPARG—urinary bladder cancer	0.0038	0.00939	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors—PPARG—urinary bladder cancer	0.0038	0.00939	CbGpPWpGaD
Tazarotene—Oedema—Mitomycin—urinary bladder cancer	0.00379	0.00921	CcSEcCtD
Tazarotene—Skin exfoliation—Etoposide—urinary bladder cancer	0.00366	0.00891	CcSEcCtD
Tazarotene—Swelling—Fluorouracil—urinary bladder cancer	0.00364	0.00884	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Epirubicin—urinary bladder cancer	0.00362	0.00879	CcSEcCtD
Tazarotene—CYP2C8—vagina—urinary bladder cancer	0.00356	0.0193	CbGeAlD
Tazarotene—RARG—Retinoic acid receptors-mediated signaling—EP300—urinary bladder cancer	0.00349	0.00863	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.00349	0.00862	CbGpPWpGaD
Tazarotene—Rash—Valrubicin—urinary bladder cancer	0.00347	0.00843	CcSEcCtD
Tazarotene—Dermatitis—Valrubicin—urinary bladder cancer	0.00347	0.00842	CcSEcCtD
Tazarotene—RARB—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.00343	0.00848	CbGpPWpGaD
Tazarotene—Dermatitis bullous—Gemcitabine—urinary bladder cancer	0.00341	0.0083	CcSEcCtD
Tazarotene—Dermatitis bullous—Fluorouracil—urinary bladder cancer	0.00336	0.00816	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Doxorubicin—urinary bladder cancer	0.00335	0.00813	CcSEcCtD
Tazarotene—Burning sensation—Methotrexate—urinary bladder cancer	0.00331	0.00804	CcSEcCtD
Tazarotene—RARA—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.00329	0.00813	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.00329	0.00813	CbGpPWpGaD
Tazarotene—Pain—Mitomycin—urinary bladder cancer	0.00324	0.00788	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.00322	0.00797	CbGpPWpGaD
Tazarotene—RARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—urinary bladder cancer	0.00318	0.00785	CbGpPWpGaD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—CDH1—urinary bladder cancer	0.00316	0.00782	CbGpPWpGaD
Tazarotene—Swelling—Etoposide—urinary bladder cancer	0.00316	0.00768	CcSEcCtD
Tazarotene—RARB—Retinoic acid receptors-mediated signaling—EP300—urinary bladder cancer	0.00313	0.00774	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.00313	0.00774	CbGpPWpGaD
Tazarotene—Burning sensation—Epirubicin—urinary bladder cancer	0.0031	0.00753	CcSEcCtD
Tazarotene—CYP2C8—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00309	0.00765	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.00309	0.00764	CbGpPWpGaD
Tazarotene—RXRB—Retinoic acid receptors-mediated signaling—EP300—urinary bladder cancer	0.003	0.00742	CbGpPWpGaD
Tazarotene—RARA—Retinoic acid receptors-mediated signaling—EP300—urinary bladder cancer	0.003	0.00742	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.003	0.00742	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.003	0.00742	CbGpPWpGaD
Tazarotene—Blister—Epirubicin—urinary bladder cancer	0.00298	0.00725	CcSEcCtD
Tazarotene—Dry skin—Fluorouracil—urinary bladder cancer	0.00294	0.00715	CcSEcCtD
Tazarotene—Burning sensation—Doxorubicin—urinary bladder cancer	0.00286	0.00696	CcSEcCtD
Tazarotene—RARB—RXR and RAR heterodimerization with other nuclear receptor—TNF—urinary bladder cancer	0.00285	0.00704	CbGpPWpGaD
Tazarotene—RXRB—Regulation of Androgen receptor activity—CREBBP—urinary bladder cancer	0.0028	0.00691	CbGpPWpGaD
Tazarotene—Blister—Doxorubicin—urinary bladder cancer	0.00276	0.00671	CcSEcCtD
Tazarotene—RARA—RXR and RAR heterodimerization with other nuclear receptor—TNF—urinary bladder cancer	0.00273	0.00675	CbGpPWpGaD
Tazarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TNF—urinary bladder cancer	0.00273	0.00675	CbGpPWpGaD
Tazarotene—Haemoglobin—Thiotepa—urinary bladder cancer	0.0027	0.00655	CcSEcCtD
Tazarotene—Haemorrhage—Thiotepa—urinary bladder cancer	0.00268	0.00652	CcSEcCtD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00267	0.00661	CbGpPWpGaD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—ERBB2—urinary bladder cancer	0.00267	0.0066	CbGpPWpGaD
Tazarotene—Stinging—Epirubicin—urinary bladder cancer	0.00265	0.00645	CcSEcCtD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00264	0.00652	CbGpPWpGaD
Tazarotene—Skin discolouration—Methotrexate—urinary bladder cancer	0.00254	0.00619	CcSEcCtD
Tazarotene—Photosensitivity reaction—Fluorouracil—urinary bladder cancer	0.00253	0.00615	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.00246	0.00608	CbGpPWpGaD
Tazarotene—Stinging—Doxorubicin—urinary bladder cancer	0.00246	0.00597	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.00244	0.00604	CbGpPWpGaD
Tazarotene—Rash—Mitomycin—urinary bladder cancer	0.00239	0.00581	CcSEcCtD
Tazarotene—Dermatitis—Mitomycin—urinary bladder cancer	0.00239	0.0058	CcSEcCtD
Tazarotene—Skin discolouration—Epirubicin—urinary bladder cancer	0.00238	0.00579	CcSEcCtD
Tazarotene—Inflammation—Methotrexate—urinary bladder cancer	0.00237	0.00576	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.00236	0.00582	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.00234	0.00579	CbGpPWpGaD
Tazarotene—Erythema—Thiotepa—urinary bladder cancer	0.00234	0.00568	CcSEcCtD
Tazarotene—Haemoglobin—Gemcitabine—urinary bladder cancer	0.00227	0.00551	CcSEcCtD
Tazarotene—Haemorrhage—Gemcitabine—urinary bladder cancer	0.00226	0.00549	CcSEcCtD
Tazarotene—Haemoglobin—Fluorouracil—urinary bladder cancer	0.00223	0.00542	CcSEcCtD
Tazarotene—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.00222	0.0054	CcSEcCtD
Tazarotene—Haemorrhage—Fluorouracil—urinary bladder cancer	0.00222	0.00539	CcSEcCtD
Tazarotene—Inflammation—Epirubicin—urinary bladder cancer	0.00222	0.00539	CcSEcCtD
Tazarotene—Skin discolouration—Doxorubicin—urinary bladder cancer	0.0022	0.00536	CcSEcCtD
Tazarotene—Skin exfoliation—Methotrexate—urinary bladder cancer	0.00219	0.00533	CcSEcCtD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00217	0.00536	CbGpPWpGaD
Tazarotene—Dermatitis contact—Epirubicin—urinary bladder cancer	0.00213	0.00517	CcSEcCtD
Tazarotene—Skin exfoliation—Epirubicin—urinary bladder cancer	0.00205	0.00499	CcSEcCtD
Tazarotene—Inflammation—Doxorubicin—urinary bladder cancer	0.00205	0.00499	CcSEcCtD
Tazarotene—RARA—Adipogenesis—NCOR1—urinary bladder cancer	0.00198	0.0049	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.00197	0.00486	CbGpPWpGaD
Tazarotene—Dermatitis contact—Doxorubicin—urinary bladder cancer	0.00197	0.00478	CcSEcCtD
Tazarotene—Erythema—Gemcitabine—urinary bladder cancer	0.00196	0.00478	CcSEcCtD
Tazarotene—Erythema—Fluorouracil—urinary bladder cancer	0.00193	0.0047	CcSEcCtD
Tazarotene—RXRB—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	0.0019	0.00471	CbGpPWpGaD
Tazarotene—Skin exfoliation—Doxorubicin—urinary bladder cancer	0.0019	0.00462	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.00189	0.00466	CbGpPWpGaD
Tazarotene—RXRB—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	0.00185	0.00458	CbGpPWpGaD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—EGFR—urinary bladder cancer	0.00185	0.00457	CbGpPWpGaD
Tazarotene—Erythema—Cisplatin—urinary bladder cancer	0.00183	0.00445	CcSEcCtD
Tazarotene—RARA—Adipogenesis—FAS—urinary bladder cancer	0.00178	0.00439	CbGpPWpGaD
Tazarotene—Eczema—Epirubicin—urinary bladder cancer	0.00174	0.00422	CcSEcCtD
Tazarotene—Discomfort—Gemcitabine—urinary bladder cancer	0.00165	0.00402	CcSEcCtD
Tazarotene—CYP2C8—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00165	0.00407	CbGpPWpGaD
Tazarotene—Dermatitis bullous—Epirubicin—urinary bladder cancer	0.00163	0.00397	CcSEcCtD
Tazarotene—Pain—Thiotepa—urinary bladder cancer	0.00163	0.00396	CcSEcCtD
Tazarotene—Discomfort—Fluorouracil—urinary bladder cancer	0.00162	0.00395	CcSEcCtD
Tazarotene—Eczema—Doxorubicin—urinary bladder cancer	0.00161	0.00391	CcSEcCtD
Tazarotene—Oedema—Gemcitabine—urinary bladder cancer	0.0016	0.0039	CcSEcCtD
Tazarotene—Oedema—Fluorouracil—urinary bladder cancer	0.00158	0.00383	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.00156	0.00387	CbGpPWpGaD
Tazarotene—Discomfort—Cisplatin—urinary bladder cancer	0.00154	0.00374	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.00154	0.0038	CbGpPWpGaD
Tazarotene—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.00151	0.00367	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.0015	0.00371	CbGpPWpGaD
Tazarotene—Oedema—Cisplatin—urinary bladder cancer	0.00149	0.00363	CcSEcCtD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—HRAS—urinary bladder cancer	0.00149	0.00367	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—GSTZ1—urinary bladder cancer	0.00148	0.00365	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.00147	0.00364	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00146	0.0036	CbGpPWpGaD
Tazarotene—Dry skin—Epirubicin—urinary bladder cancer	0.00143	0.00348	CcSEcCtD
Tazarotene—RARA—Adipogenesis—PPARG—urinary bladder cancer	0.00142	0.00351	CbGpPWpGaD
Tazarotene—Discomfort—Etoposide—urinary bladder cancer	0.00141	0.00343	CcSEcCtD
Tazarotene—CYP2C8—Biological oxidations—GSTO2—urinary bladder cancer	0.0014	0.00346	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—NAT1—urinary bladder cancer	0.0014	0.00346	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00138	0.00341	CbGpPWpGaD
Tazarotene—Pain—Gemcitabine—urinary bladder cancer	0.00137	0.00333	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.00136	0.00336	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—RB1—urinary bladder cancer	0.00136	0.00336	CbGpPWpGaD
Tazarotene—Pruritus—Thiotepa—urinary bladder cancer	0.00135	0.00328	CcSEcCtD
Tazarotene—Pain—Fluorouracil—urinary bladder cancer	0.00135	0.00328	CcSEcCtD
Tazarotene—RARA—Adipogenesis—IGF1—urinary bladder cancer	0.00135	0.00333	CbGpPWpGaD
Tazarotene—Dry skin—Doxorubicin—urinary bladder cancer	0.00132	0.00322	CcSEcCtD
Tazarotene—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.00132	0.0032	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.00131	0.00323	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—UGT2B7—urinary bladder cancer	0.00128	0.00316	CbGpPWpGaD
Tazarotene—Pain—Cisplatin—urinary bladder cancer	0.00128	0.00311	CcSEcCtD
Tazarotene—CYP2C8—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00126	0.00312	CbGpPWpGaD
Tazarotene—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.00123	0.00299	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	0.0012	0.00297	CbGpPWpGaD
Tazarotene—Rash—Thiotepa—urinary bladder cancer	0.0012	0.00292	CcSEcCtD
Tazarotene—Dermatitis—Thiotepa—urinary bladder cancer	0.0012	0.00292	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	0.0012	0.00296	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	0.00119	0.00295	CbGpPWpGaD
Tazarotene—Pain—Etoposide—urinary bladder cancer	0.00117	0.00285	CcSEcCtD
Tazarotene—Haemoglobin—Methotrexate—urinary bladder cancer	0.00116	0.00282	CcSEcCtD
Tazarotene—Haemorrhage—Methotrexate—urinary bladder cancer	0.00115	0.00281	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	0.00115	0.00285	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP4B1—urinary bladder cancer	0.00115	0.00285	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	0.00115	0.00284	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	0.00114	0.00283	CbGpPWpGaD
Tazarotene—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.00114	0.00277	CcSEcCtD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00114	0.00281	CbGpPWpGaD
Tazarotene—Pruritus—Gemcitabine—urinary bladder cancer	0.00113	0.00276	CcSEcCtD
Tazarotene—Pruritus—Fluorouracil—urinary bladder cancer	0.00112	0.00271	CcSEcCtD
Tazarotene—RARG—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.00109	0.00269	CbGpPWpGaD
Tazarotene—Haemoglobin—Epirubicin—urinary bladder cancer	0.00109	0.00264	CcSEcCtD
Tazarotene—Haemorrhage—Epirubicin—urinary bladder cancer	0.00108	0.00263	CcSEcCtD
Tazarotene—Oedema peripheral—Epirubicin—urinary bladder cancer	0.00106	0.00259	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	0.00105	0.00258	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	0.00103	0.00255	CbGpPWpGaD
Tazarotene—Rash—Gemcitabine—urinary bladder cancer	0.00101	0.00246	CcSEcCtD
Tazarotene—Dermatitis—Gemcitabine—urinary bladder cancer	0.00101	0.00246	CcSEcCtD
Tazarotene—Erythema—Methotrexate—urinary bladder cancer	0.001	0.00244	CcSEcCtD
Tazarotene—Haemoglobin—Doxorubicin—urinary bladder cancer	0.001	0.00244	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	0.001	0.00248	CbGpPWpGaD
Tazarotene—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000999	0.00243	CcSEcCtD
Tazarotene—Rash—Fluorouracil—urinary bladder cancer	0.000994	0.00242	CcSEcCtD
Tazarotene—Dermatitis—Fluorouracil—urinary bladder cancer	0.000993	0.00241	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	0.00099	0.00245	CbGpPWpGaD
Tazarotene—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000984	0.00239	CcSEcCtD
Tazarotene—RARB—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000977	0.00241	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—CDKN1A—urinary bladder cancer	0.000976	0.00241	CbGpPWpGaD
Tazarotene—CYP2C8—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000974	0.00241	CbGpPWpGaD
Tazarotene—Pruritus—Etoposide—urinary bladder cancer	0.000969	0.00235	CcSEcCtD
Tazarotene—Rash—Cisplatin—urinary bladder cancer	0.000942	0.00229	CcSEcCtD
Tazarotene—Dermatitis—Cisplatin—urinary bladder cancer	0.000941	0.00229	CcSEcCtD
Tazarotene—Erythema—Epirubicin—urinary bladder cancer	0.00094	0.00229	CcSEcCtD
Tazarotene—RARA—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000937	0.00232	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000937	0.00232	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	0.000876	0.00216	CbGpPWpGaD
Tazarotene—Erythema—Doxorubicin—urinary bladder cancer	0.00087	0.00211	CcSEcCtD
Tazarotene—Rash—Etoposide—urinary bladder cancer	0.000863	0.0021	CcSEcCtD
Tazarotene—Dermatitis—Etoposide—urinary bladder cancer	0.000862	0.0021	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	0.000856	0.00212	CbGpPWpGaD
Tazarotene—Discomfort—Methotrexate—urinary bladder cancer	0.000845	0.00205	CcSEcCtD
Tazarotene—RARG—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000841	0.00208	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	0.000839	0.00207	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	0.000821	0.00203	CbGpPWpGaD
Tazarotene—Discomfort—Epirubicin—urinary bladder cancer	0.000791	0.00192	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	0.000774	0.00191	CbGpPWpGaD
Tazarotene—Oedema—Epirubicin—urinary bladder cancer	0.000767	0.00187	CcSEcCtD
Tazarotene—CYP2C8—Biological oxidations—NAT2—urinary bladder cancer	0.000766	0.00189	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000756	0.00187	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000754	0.00186	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—TNF—urinary bladder cancer	0.000754	0.00186	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	0.000748	0.00185	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	0.000747	0.00185	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	0.000742	0.00183	CbGpPWpGaD
Tazarotene—Discomfort—Doxorubicin—urinary bladder cancer	0.000732	0.00178	CcSEcCtD
Tazarotene—RXRB—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000723	0.00179	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000723	0.00179	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	0.000718	0.00177	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	0.000716	0.00177	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	0.000712	0.00176	CbGpPWpGaD
Tazarotene—Oedema—Doxorubicin—urinary bladder cancer	0.00071	0.00173	CcSEcCtD
Tazarotene—Pain—Methotrexate—urinary bladder cancer	0.000701	0.0017	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	0.000692	0.00171	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	0.000683	0.00169	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	0.000664	0.00164	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.000661	0.00163	CbGpPWpGaD
Tazarotene—Pain—Epirubicin—urinary bladder cancer	0.000656	0.0016	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	0.000621	0.00153	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—HPGDS—urinary bladder cancer	0.000613	0.00151	CbGpPWpGaD
Tazarotene—Pain—Doxorubicin—urinary bladder cancer	0.000607	0.00148	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	0.000607	0.0015	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000603	0.00149	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—SMC1A—urinary bladder cancer	0.000602	0.00149	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	0.000595	0.00147	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—GSTT1—urinary bladder cancer	0.000594	0.00147	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.000593	0.00146	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	0.000582	0.00144	CbGpPWpGaD
Tazarotene—Pruritus—Methotrexate—urinary bladder cancer	0.00058	0.00141	CcSEcCtD
Tazarotene—RARG—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000579	0.00143	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	0.000578	0.00143	CbGpPWpGaD
Tazarotene—CYP2C8—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000573	0.00142	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	0.000573	0.00142	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.000568	0.0014	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.000568	0.0014	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	0.000554	0.00137	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	0.00055	0.00136	CbGpPWpGaD
Tazarotene—Pruritus—Epirubicin—urinary bladder cancer	0.000543	0.00132	CcSEcCtD
Tazarotene—RARB—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000541	0.00134	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—SMC1A—urinary bladder cancer	0.00054	0.00133	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—ESR2—urinary bladder cancer	0.000525	0.0013	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000519	0.00128	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000518	0.00128	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000518	0.00128	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—SMC1A—urinary bladder cancer	0.000518	0.00128	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—SMC1A—urinary bladder cancer	0.000518	0.00128	CbGpPWpGaD
Tazarotene—Rash—Methotrexate—urinary bladder cancer	0.000517	0.00126	CcSEcCtD
Tazarotene—Dermatitis—Methotrexate—urinary bladder cancer	0.000517	0.00126	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	0.00051	0.00126	CbGpPWpGaD
Tazarotene—Pruritus—Doxorubicin—urinary bladder cancer	0.000502	0.00122	CcSEcCtD
Tazarotene—RXRB—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000498	0.00123	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000498	0.00123	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	0.000489	0.00121	CbGpPWpGaD
Tazarotene—Rash—Epirubicin—urinary bladder cancer	0.000484	0.00118	CcSEcCtD
Tazarotene—Dermatitis—Epirubicin—urinary bladder cancer	0.000483	0.00118	CcSEcCtD
Tazarotene—RARB—Gene Expression—ESR2—urinary bladder cancer	0.00047	0.00116	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—ESR2—urinary bladder cancer	0.000451	0.00111	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—ESR2—urinary bladder cancer	0.000451	0.00111	CbGpPWpGaD
Tazarotene—Rash—Doxorubicin—urinary bladder cancer	0.000448	0.00109	CcSEcCtD
Tazarotene—Dermatitis—Doxorubicin—urinary bladder cancer	0.000447	0.00109	CcSEcCtD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000442	0.00109	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—GSTP1—urinary bladder cancer	0.000412	0.00102	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000406	0.001	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—NCOR1—urinary bladder cancer	0.000405	0.001	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—ERCC2—urinary bladder cancer	0.000381	0.000941	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	0.000379	0.000936	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000373	0.000923	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—NCOR1—urinary bladder cancer	0.000363	0.000898	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—NCOR1—urinary bladder cancer	0.000348	0.000861	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—NCOR1—urinary bladder cancer	0.000348	0.000861	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—MYC—urinary bladder cancer	0.000344	0.000849	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—ERCC2—urinary bladder cancer	0.000342	0.000844	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—ERCC2—urinary bladder cancer	0.000327	0.000809	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—ERCC2—urinary bladder cancer	0.000327	0.000809	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—ESR1—urinary bladder cancer	0.000318	0.000786	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—MYC—urinary bladder cancer	0.000308	0.000762	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—MYC—urinary bladder cancer	0.000296	0.00073	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—MYC—urinary bladder cancer	0.000296	0.00073	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—PPARG—urinary bladder cancer	0.00029	0.000717	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—ESR1—urinary bladder cancer	0.000285	0.000705	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—CREBBP—urinary bladder cancer	0.000279	0.000689	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—ESR1—urinary bladder cancer	0.000274	0.000676	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—ESR1—urinary bladder cancer	0.000274	0.000676	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—PPARG—urinary bladder cancer	0.00026	0.000643	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	0.000252	0.000624	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—CREBBP—urinary bladder cancer	0.00025	0.000618	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—PPARG—urinary bladder cancer	0.00025	0.000617	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—PPARG—urinary bladder cancer	0.00025	0.000617	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—CREBBP—urinary bladder cancer	0.00024	0.000593	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—CREBBP—urinary bladder cancer	0.00024	0.000593	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	0.000239	0.000591	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NAT1—urinary bladder cancer	0.000239	0.000591	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000235	0.000581	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	0.000219	0.000541	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	0.000197	0.000487	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	0.000186	0.00046	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	0.000181	0.000448	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—MYC—urinary bladder cancer	0.000165	0.000409	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—MYC—urinary bladder cancer	0.000148	0.000367	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000145	0.000359	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—TYMP—urinary bladder cancer	0.000145	0.000358	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—MYC—urinary bladder cancer	0.000142	0.000352	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—MYC—urinary bladder cancer	0.000142	0.000352	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000139	0.000344	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NAT2—urinary bladder cancer	0.000131	0.000324	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—RRM2—urinary bladder cancer	0.000113	0.00028	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	0.000105	0.000259	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ENO2—urinary bladder cancer	0.000105	0.000259	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000104	0.000257	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	0.000102	0.000251	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.0001	0.000247	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NQO1—urinary bladder cancer	8.45e-05	0.000209	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.19e-05	0.000203	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.15e-05	0.000177	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	7.04e-05	0.000174	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.82e-05	0.000168	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—TYMS—urinary bladder cancer	6.55e-05	0.000162	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	6.47e-05	0.00016	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	6.47e-05	0.00016	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GPX1—urinary bladder cancer	6.2e-05	0.000153	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	6.09e-05	0.00015	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	5.72e-05	0.000141	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PPARG—urinary bladder cancer	4.64e-05	0.000115	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	4.46e-05	0.00011	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	3.65e-05	9.02e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PTEN—urinary bladder cancer	3.18e-05	7.87e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—EP300—urinary bladder cancer	3.04e-05	7.5e-05	CbGpPWpGaD
